Relationship between neuropathology and disease progression in the SOD1G93A ALS mouse

Experimental Neurology

Volumn 227, Issue 2, 2011, Pages 287-295

  Yang, Wendy W ^a   Sidman, Richard L ^b   Taksir, Tatyana V ^a   Treleaven, Christopher M ^a   Fidler, Jonathan A ^a   Cheng, Seng H ^a   Dodge, James C ^a   Shihabuddin, Lamya S ^a  

^a GENZYME CORPORATION   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Amyotrophic lateral sclerosis; Astroglia; Disease progression; Microglia; Motor neuron; SOD1G93A mouse; Ventrolateral thalamus

Indexed keywords

ADENOSINE; COPPER ZINC SUPEROXIDE DISMUTASE; GUANOSINE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; ASTROCYTOSIS; CELL ACTIVATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DYING; FEMALE; MALE; MICROGLIA; MOTOR CORTEX; MOTOR NEURON DISEASE; MOUSE; NERVE CELL DEGENERATION; NERVE CELL NECROSIS; NEUROMODULATION; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SPINAL CORD; SYMPTOMATOLOGY; THALAMUS VENTRAL NUCLEUS; TRIGEMINAL NUCLEUS;

ALANINE; AMINO ACID SUBSTITUTION; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GLYCINE; HUMANS; MALE; MICE; MICE, TRANSGENIC; SUPEROXIDE DISMUTASE;

EID: 78651441518     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.11.019     Document Type: Article

References (68)

1. Abe K., Pan L.H., Watanabe M., Kato T., Itoyama Y. Induction of nitrotyrosine-like immunoreactivity in the lower motor neuron of amyotrophic lateral sclerosis. Neurosci. Lett. 1995, 199:152-154.
2. Alexianu M.E., Kozovska M., Appel S.H. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology 2001, 57:1282-1289.
3. Aoki M., Kato S., Nagai M., Itoyama Y. Development of a rat model of amyotrophic lateral sclerosis expressing a human SOD1 transgene. Neuropathology 2005, 25:365-370.
4. Banati R.B., Schubert P., Rothe G., Gehrmann J., Rudolphi K., Valet G., et al. Modulation of intracellular formation of reactive oxygen intermediates in peritoneal macrophages and microglia/brain macrophages by propentofylline. J. Cereb. Blood Flow Metab. 1994, 14:145-149.
5. Beal M.F., Ferrante R.J., Browne S.E., Matthews R.T., Kowall N.W., Brown R.H. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann. Neurol. 1997, 42:644-654.
6. Beckman J.S., Carson M., Smith C.D., Koppenol W.H. ALS, SOD and peroxynitrite. Nature 1993, 364:584.
7. Beers D.R., Henkel J.S., Xiao Q., Zhao W., Wang J., Yen A.A., et al. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc. Natl Acad. Sci. USA 2006, 103:16021-16026.
8. Boillee S., Vande Velde C., Cleveland D.W. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 2006, 52:39-59.
9. Boillee S., Yamanaka K., Lobsiger C.S., Copeland N.G., Jenkins N.A., Kassiotis G., et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006, 312:1389-1392.
10. Bruijn L.I., Becher M.W., Lee M.K., Anderson K.L., Jenkins N.A., Copeland N.G., et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 1997, 18:327-338.
11. Bruijn L.I., Houseweart M.K., Kato S., Anderson K.L., Anderson S.D., Ohama E., et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 1998, 281:1851-1854.
12. Catania M.V., Aronica E., Yankaya B., Troost D. Increased expression of neuronal nitric oxide synthase spliced variants in reactive astrocytes of amyotrophic lateral sclerosis human spinal cord. J. Neurosci. 2001, 21:RC148.
13. Cha C.I., Chung Y.H., Shin C.M., Shin D.H., Kim Y.S., Gurney M.E., et al. Immunocytochemical study on the distribution of nitrotyrosine in the brain of the transgenic mice expressing a human Cu/Zn SOD mutation. Brain Res. 2000, 853:156-161.
14. Cha C.I., Kim J.M., Shin D.H., Kim Y.S., Kim J., Gurney M.E., et al. Reactive astrocytes express nitric oxide synthase in the spinal cord of transgenic mice expressing a human Cu/Zn SOD mutation. NeuroReport 1998, 9:15036.
15. Chiu A.Y., Zhai P., Dal Canto M.C., Peters T.M., Kwon Y.W., Prattis S.M., et al. Age-dependent penetrance of disease in a transgenic mouse model of familial amyotrophic lateral sclerosis. Mol. Cell. Neurosci. 1995, 6:349-362.
16. Clement A.M., Nguyen M.D., Roberts E.A., Garcia M.L., Boillee S., Rule M., et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 2003, 302:113-117.
17. Dal Canto M.C., Gurney M.E. Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis. Am. J. Pathol. 1994, 145:1271-1279.
18. Dal Canto M.C., Gurney M.E. A low expressor line of transgenic mice carrying a mutant human Cu, Zn superoxide dismutase (SOD1) gene develops pathological changes that most closely resemble those in human amyotrophic lateral sclerosis. Acta Neuropathol. 1997, 93:537-550.
19. Di Giorgio F.P., Carrasco M.A., Siao M.C., Maniatis T., Eggan K. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat. Neurosci. 2007, 10:608-614.
20. Dodge J.C., Haidet A.M., Yang W., Passini M.A., Hester M., Clarke J., et al. Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity. Mol. Ther. 2008, 16:1056-1064.
21. Ferrante R.J., Shinobu L.A., Schulz J.B., Matthews R.T., Thomas C.E., Kowall N.W., et al. Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Ann. Neurol. 1997, 42:326-334.
22. Gehrmann J., Matsumoto Y., Kreutzberg G.W. Microglia: intrinsic immuneffector cell of the brain. Brain Res. Brain Res. Rev. 1995, 20:269-287.
23. Gowing G., Philips T., Van Wijmeersch B., Audet J.N., Dewil M., Van Den Bosch L., et al. Ablation of proliferating microglia does not affect motor neuron degeneration in amyotrophic lateral sclerosis caused by mutant superoxide dismutase. J. Neurosci. 2008, 28:10234-10244.
24. Gordon P.H., Moore D.H., Miller R.G., Florence J.M., Verheijde J.L., Doorish C., et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007, 6:1045-1053.
25. Guegan C., Przedborski S. Programmed cell death in amyotrophic lateral sclerosis. J. Clin. Invest. 2003, 111:153-161.
26. Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994, 264:1772-1775.
27. Gurney M.E., Cutting F.B., Zhai P., Doble A., Taylor C.P., Andrus P.K., et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol. 1996, 39:147-157.
28. Hall E.D., Oostveen J.A., Gurney M.E. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 1998, 23:249-256.
29. Henkel J.S., Engelhardt J.I., Siklos L., Simpson E.P., Kim S.H., Pan T., et al. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann. Neurol. 2004, 55:221-235.
30. Holevinsky K.O., Nelson D.J. Simultaneous detection of free radical release and membrane current during phagocytosis. J. Biol. Chem. 1995, 270:8328-8336.
31. Howland D.S., Liu J., She Y., Goad B., Maragakis N.J., Kim B., et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc. Natl Acad. Sci. USA 2002, 99:1604-1609.
32. Hu S., Sheng W.S., Peterson P.K., Chao C.C. Cytokine modulation of murine microglial cell superoxide production. Glia 1995, 13:45-50.
33. Hu S., Chao C.C., Khanna K.V., Gekker G., Peterson P.K., Molitor T.W. Cytokine and free radical production by porcine microglia. Clin. Immunol. Immunopathol. 1996, 78:93-96.
34. Ilieva H., Polymenidou M., Cleveland D.W. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol. 2009, 187:761-772.
35. Jaarsma D., Teuling E., Haasdijk E.D., De Zeeuw C.I., Hoogenraad C.C. Neuron-specific expression of mutant superoxide dismutase is sufficient to induce amyotrophic lateral sclerosis in transgenic mice. J. Neurosci. 2008, 28:2075-2088.
36. Johnston J.A., Dalton M.J., Gurney M.E., Kopito R.R. Formation of high molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proc. Natl Acad. Sci. USA 2000, 97:12571-12576.
37. Julien J.P. Amyotrophic lateral sclerosis. Unfolding the toxicity of the misfolded. Cell 2001, 104:581-591.
38. Kato S., Takikawa M., Nakashima K., Hirano A., Cleveland D.W., Kusaka H., et al. New consensus research on neuropathological aspects of familial amyotrophic lateral sclerosis with superoxide dismutase 1 (SOD1) gene mutations: inclusions containing SOD1 in neurons and astrocytes. Amyotroph Lateral Scler Other Motor Neuron Disord 2000, 1:163-184.
39. Keller A.F., Gravel M., Kriz J. Live imaging of amyotrophic lateral sclerosis pathogenesis: disease onset is characterized by marked induction of GFAP in Schwann cells. Glia 2009, 57:1130-1142.
40. Kriz J., Nguyen M.D., Julien J.P. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2002, 10:268-278.
41. Leigh P.N., Swash M. Cytoskeletal pathology in motor neuron diseases. Adv. Neurol. 1991, 56:115-124.
42. Lepore A.C., Haenggeli C., Gasmi M., Bishop K.M., Bartus R.T., Maragakis N.J., Rothstein J.D. Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS. Brain Res. 2007, 1185:256-265.
43. Lepore A.C., Dejea C., Carmen J., Rauck B., Kerr D.A., Sofroniew M.V., et al. Selective ablation of proliferating astrocytes does not affect disease outcome in acute or chronic models of motor neuron degeneration. Exp. Neurol. 2008, 211:423-432.
44. Lepore A.C., Rauck B., Dejea C., Pardo A.C., Rao M.S., Rothstein J.D., et al. Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat. Neurosci. 2008, 11:1294-1301.
45. Lino M.M., Schneider C., Caroni P. Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. J. Neurosci. 2002, 22:4825-4832.
46. Magnus T., Carmen J., Deleon J., Xue H., Pardo A.C., Lepore A.C., et al. Adult glial precursor proliferation in mutant SOD1G93A mice. Glia 2008, 56:200-208.
47. Maragakis N.J., Rothstein J.D. Mechanisms of disease: astrocytes in neurodegenerative disease. Nat. Clin. Pract. Neurol. 2006, 2:679-689.
48. Marchetto M.C., Muotri A.R., Mu Y., Smith A.M., Cezar G.G., Gage F.H. Non-cell-autonomous effect of human SOD1 G37R astrocytes on motor neurons derived from human embryonic stem cells. Cell Stem Cell 2008, 3:649-657.
49. McGeer P.L., McGeer E.G. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Brain Res. Rev. 1995, 21:195-218.
50. Minghetti L., Levi G. Microglia as effector cells in brain damage and repair: focus on prostanoids and nitric oxide. Prog. Neurobiol. 1998, 54:99-125.
51. Nagai M., Aoki M., Miyoshi I., Kato M., Pasinelli P., Kasai N., et al. Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: associated mutations develop motor neuron disease. J. Neurosci. 2001, 21:9246-9254.
52. Nagai M., Re D.B., Nagata T., Chalazonitis A., Jessell T.M., Wichterle H., et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat. Neurosci. 2007, 10:615-622.
53. Pramatarova A., Laganiere J., Roussel J., Brisebois K., Rouleau G.A. Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J. Neurosci. 2001, 21:3369-3374.
54. Reaume A.G., Elliott J.L., Hoffman E.K., Kowall N.W., Ferrante R.J., Siwek D.F., et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat. Genet. 1996, 13:43-47.
55. Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362:59-62.
56. Sargsyan S.A., Monk P.N., Shaw P.J. Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis. Glia 2005, 51:241-253.
57. Schmued L.C., Stowers C.C., Scallet A.C., Xu L. Fluoro-Jade C results in ultra high resolution and contrast labeling of degenerating neurons. Brain Res. 2005, 1035:24-31.
58. Shihabuddin L.S., Numan S., Huff M.R., Dodge J.C., Clarke J., Macauley S.L. Intracerebral transplantation of adult mouse neural progenitor cells into the Niemann-Pick-A mouse leads to a marked decrease in lysosomal storage pathology. J. Neurosci. 2004, 24:10642-10651.
59. Staats K.A., Van Den Bosch L. Astrocytes in amyotrophic lateral sclerosis: direct effects on motor neuron survival. J. Biol. Phys. 2009, 35:337-346.
60. Teng Y.D., Choi H., Huang W., Onario R.C., Frontera W.R., Snyder E.Y., et al. Therapeutic effects of clenbuterol in a murine model of amyotrophic lateral sclerosis. Neurosci. Lett. 2006, 397:155-158.
61. Urushitani M., Shimohama S. The role of nitric oxide in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 2001, 2:71-81.
62. Wang J., Xu G., Gonzales V., Coonfield M., Fromholt D., Copeland N.G., et al. Fibrillar inclusions and motor neuron degeneration in transgenic mice expressing superoxide dismutase 1 with a disrupted copper-binding site. Neurobiol. Dis. 2002, 10:128-138.
63. Watanabe M., Dykes-Hoberg M., Culotta V.C., Price D.L., Wong P.C., Rothstein J.D. Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiol. Dis. 2001, 8:933-941.
64. Wong P.C., Pardo C.A., Borchelt D.R., Lee M.K., Copeland N.G., Jenkins N.A., et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995, 14:1105-1116.
65. Xiao Q., Zhao W., Beers D.R., Yen A.A., Xie W., Henkel J.S., et al. Mutant SOD1(G93A) microglia are more neurotoxic relative to wild-type microglia. J. Neurochem. 2007, 102:2008-2019.
66. Yamanaka K., Boillee S., Roberts E.A., Garcia M.L., McAlonis-Downes M., et al. Mutant SOD1 in cell types other than motor neurons and oligodndrocytes accelerates onset of disease in ALS mice. Proc. Natl Acad. Sci. USA 2008, 105:7594-7599.
67. Yamanaka K., Chun S.J., Boillee S., Fujimori-Tonou N., Yamashita H., Gutmann D.H. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat. Neurosci. 2008, 11:251-253.
68. Yoshida T., Tanaka M., Sotomatsu A., Hirai S. Activated microglia cause superoxide-mediated release of iron from ferritin. Neurosci. Lett. 1995, 190:21-24.